What are the treatment and prevention options for a patient suspected of having Hepatitis A?

Hepatitis A: Treatment and Prevention

Treatment Approach

Hepatitis A requires only supportive care, as no virus-specific treatment has been proven effective and the infection is self-limited without chronic sequelae. 1

Supportive Management

• Provide hydration, rest, and symptomatic relief as the cornerstone of treatment 2, 3
• Hospitalize patients who develop dehydration from nausea and vomiting or those showing signs of fulminant hepatitis 1, 2
• Avoid all hepatotoxic medications and drugs metabolized by the liver during acute illness 1, 3
• No specific dietary restrictions or activity limitations are necessary for uncomplicated cases 1

Monitoring for Complications

• Monitor liver function tests (ALT, AST, bilirubin) and coagulation studies (INR) in patients with severe jaundice 2, 4
• Watch closely for acute liver failure, indicated by prolonged INR and hepatic encephalopathy, which occurs in <1% of cases but carries significant mortality 2, 5, 4
• Recognize that 10-15% of symptomatic patients experience prolonged or relapsing disease lasting up to 6 months, with approximately 20% having multiple relapses 3, 5
• Be aware that mortality risk increases with age, reaching 1.8% in adults over 50 years compared to 0.3-0.6% overall 3

Prevention Strategies

Preexposure Prophylaxis (Vaccination)

Hepatitis A vaccine is the most effective means of preventing HAV infection, with 94-100% efficacy. 1

• Administer as a two-dose series, with 99-100% of persons responding to the first dose and the second dose providing long-term protection 1
• Vaccinate all men who have sex with men (both adolescents and adults) 1
• Vaccinate illegal drug users (injecting and non-injecting) if local epidemiologic evidence indicates outbreaks 1
• Consider routine vaccination for all residents of high-risk facilities to prevent future outbreaks 2

Postexposure Prophylaxis

For recent exposures (within 2 weeks), hepatitis A vaccine alone is now preferred for healthy unvaccinated individuals. 2, 3

• Administer vaccine as soon as possible after exposure to all uninfected individuals 2
• Reserve immune globulin (IG) for specific high-risk groups: children under 12 months, immunocompromised persons, those with chronic liver disease, and those with vaccine contraindications 3
• Give IG at 0.02 mL/kg intramuscularly within 2 weeks of exposure when indicated, as efficacy beyond 2 weeks is not established 1
• Vaccine and IG can be administered simultaneously at different anatomic injection sites if both are indicated 1, 2
• Persons who received at least one vaccine dose ≥1 month before exposure do not need IG 1

Specific Exposure Situations Requiring Postexposure Prophylaxis

Close Personal Contact:

• Administer prophylaxis to all household and sexual contacts of serologically confirmed cases 1
• Treat persons who shared illicit drugs with confirmed cases 1
• Consider prophylaxis for regular babysitters and others with ongoing close contact 1

Child Care Centers:

• Provide prophylaxis to all staff and attendees if one or more cases occur in children or employees, or if cases occur in two or more households of attendees 1
• In centers without diaper-wearing children, limit prophylaxis to classroom contacts only 1

Food Handler Exposure:

• Administer prophylaxis to other food handlers at the same establishment 1
• Consider prophylaxis for patrons only if: the infected food handler directly handled uncooked or post-cooking foods AND had diarrhea or poor hygiene AND patrons can be identified and treated within 2 weeks 1

Infection Control Measures

• Ensure proper handwashing facilities and encourage frequent handwashing among all individuals 2
• Maintain proper sanitation and safe drinking water supply to prevent transmission 2
• Recognize that maximal infectivity occurs during the 2 weeks before jaundice onset, when viral concentration in feces is highest 3
• Be aware that children can shed virus for up to 10 weeks after illness onset 3

Common Pitfalls to Avoid

• Do not delay postexposure prophylaxis for serologic screening of contacts, as this reduces effectiveness 1
• Do not routinely give IG in schools or workplaces for single cases when the source is outside these settings 1
• Do not rely on clinical diagnosis alone—always confirm with IgM anti-HAV testing before treating contacts 1, 2, 3
• Do not assume all jaundiced patients have simple hepatitis A—monitor coagulation studies to detect progression to acute liver failure early 2, 4